Cipher Pharmaceuticals (CPH) Trading Down 0.2%
Shares of Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) fell 0.2% on Monday . The company traded as low as C$5.10 and last traded at C$5.11. 9,600 shares were traded during trading, a decline of 38% from the average session volume of 15,602 shares. The stock had previously closed at C$5.10.
A number of brokerages recently weighed in on CPH. TD Securities upped their price target on shares of Cipher Pharmaceuticals from C$5.50 to C$6.50 in a research report on Monday, August 14th. Bloom Burton cut shares of Cipher Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 14th.
In other Cipher Pharmaceuticals news, Director Harold Morton Wolkin purchased 35,000 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The stock was purchased at an average cost of C$4.69 per share, with a total value of C$164,150.00.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals Inc, together with its subsidiaries, operates as a specialty pharmaceutical dermatology company in South America, Canada, and the United States. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.
Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.